Watermark
  Back to Search Results

BGB-A317-302

Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-302

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03430843

EudraCT or EUCT Number Info icon SVG graphic used for tooltips or additional information.

2017

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20171026

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary